De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

ANI Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

De CEO ANI Pharmaceuticals' is Nikhil Lalwani, benoemd in Sep2020, heeft een ambtstermijn van 4.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.08M, bestaande uit 9.5% salaris en 90.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.92% van de aandelen van het bedrijf, ter waarde € 20.15M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.9 jaar en 4.1 jaar.

Belangrijke informatie

Nikhil Lalwani

Algemeen directeur

US$8.1m

Totale compensatie

Percentage CEO-salaris	9.5%
Dienstverband CEO	4.1yrs
Eigendom CEO	1.9%
Management gemiddelde ambtstermijn	2.9yrs
Gemiddelde ambtstermijn bestuur	4.1yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Nikhil Lalwani's beloning veranderd ten opzichte van ANI Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	US$23m
Mar 31 2024	n/a	n/a	US$31m
Dec 31 2023	US$8m	US$764k	US$15m
Sep 30 2023	n/a	n/a	US$10m
Jun 30 2023	n/a	n/a	-US$8m
Mar 31 2023	n/a	n/a	-US$28m
Dec 31 2022	US$5m	US$737k	-US$50m
Sep 30 2022	n/a	n/a	-US$69m
Jun 30 2022	n/a	n/a	-US$65m
Mar 31 2022	n/a	n/a	-US$63m
Dec 31 2021	US$7m	US$715k	-US$43m
Sep 30 2021	n/a	n/a	-US$22m
Jun 30 2021	n/a	n/a	-US$17m
Mar 31 2021	n/a	n/a	-US$15m
Dec 31 2020	US$4m	US$199k	-US$23m

Compensatie versus markt: De totale vergoeding ($USD 8.08M ) Nikhil } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.42M ).

Compensatie versus inkomsten: De vergoeding van Nikhil is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Nikhil Lalwani (46 yo)

4.1yrs

Tenure

US$8,078,353

Compensatie

Mr. Nikhil Lalwani served as a Director of Association for Accessible Medicines. He served as the Chief Executive Officer of InvaGen Pharmaceuticals, Inc. since October 24, 2016. Mr. Lalwani is a seasoned...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Nikhil Lalwani	President	4.1yrs	US$8.08m	1.92% $ 20.1m
Stephen Carey	Senior VP of Finance & CFO	8.4yrs	US$2.58m	0.83% $ 8.7m
Chad Gassert	Senior Vice President of Corporate Development & Strategy	2.9yrs	US$1.90m	1.24% $ 13.1m
Christopher Mutz	Senior Vp & Head of Rare Disease	3.7yrs	US$1.91m	0.43% $ 4.5m
Ori Gutwerg	Senior Vice President of Generics	3.7yrs	US$1.94m	0.40% $ 4.2m
Muthusamy Shanmugam	Head of R&D	2.9yrs	geen gegevens	0.26% $ 2.7m
James Marken	Senior Vice President of Operations	8.4yrs	US$1.43m	0.60% $ 6.3m
Elizabeth Powell	Chief Compliance Officer & Head of Legal of Rare Disease	2.7yrs	geen gegevens	geen gegevens
Meredith Cook	Senior VP	2.3yrs	geen gegevens	0.29% $ 3.1m
Krista Davis	Senior VP & Chief Human Resources Officer	2.1yrs	geen gegevens	0.26% $ 2.7m
Mary Pao	Chief Medical Officer	2.7yrs	geen gegevens	geen gegevens
Thomas Rowland	Senior VP & Head of Established Brands	2.9yrs	geen gegevens	0.17% $ 1.8m

2.9yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van BSFA wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Nikhil Lalwani	President	4.1yrs	US$8.08m	1.92% $ 20.1m
Muthusamy Shanmugam	Head of R&D	2.9yrs	geen gegevens	0.26% $ 2.7m
Patrick Walsh	Independent Chairman	6.4yrs	US$422.21k	0.38% $ 4.0m
Antonio Pera	Independent Director	4.2yrs	US$393.25k	0.16% $ 1.7m
Thomas Haughey	Independent Director	6.4yrs	US$412.21k	0.26% $ 2.8m
Jeanne Thoma	Independent Director	4.2yrs	US$395.75k	0.21% $ 2.2m
Renee Tannenbaum	Independent Director	2.6yrs	US$392.37k	0.12% $ 1.2m
Matthew Leonard	Independent Director	1.2yrs	US$470.76k	0.061% $ 644.8k

4.1yrs

Gemiddelde duur

61.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BSFA wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.1 jaar).

ANI Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Senior VP of Finance & CFO recently sold €292k worth of stock

President recently sold €1.0m worth of stock

ANI Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

Independent Director recently sold €420k worth of stock

Head of Rare Disease recently sold €148k worth of stock

ANI Pharmaceuticals, Inc. Announces Board Changes

Recent updates

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) completed the acquisition of Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others.

Alimera Sciences, Inc. Takes Legal Action Against ANI Pharmaceuticals, Inc. to Enforce Merger Agreement

Second quarter 2024 earnings released: US$0.14 loss per share (vs US$0.30 profit in 2Q 2023)

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2024

ANI Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of L-Glutamine Oral Powder

ANI Pharmaceuticals, Inc.(NasdaqGM:ANIP) dropped from Russell 3000E Value Index

ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) signed a definitive agreement to acquire Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others for approximately $300 million.

Senior VP of Finance & CFO recently sold €292k worth of stock

President recently sold €1.0m worth of stock

ANI Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: EPS: US$0.93 (vs US$0.056 in 1Q 2023)

ANI Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 10, 2024

ANI Pharmaceuticals, Inc. Announces the Launch of Baclofen Oral Suspension

ANI Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

ANI Pharmaceuticals, Inc. Announces the Launch of Levofloxacin Oral Solution, USP

Independent Director recently sold €420k worth of stock

Full year 2023 earnings released: EPS: US$0.95 (vs US$3.05 loss in FY 2022)

ANI Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

ANI Pharmaceuticals, Inc. to Report Second Half, 2023 Results on Feb 29, 2024

ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Indomethacin Oral Suspension, USP

Head of Rare Disease recently sold €148k worth of stock

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: US$0.51 (vs US$0.55 loss in 3Q 2022)

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2023

ANI Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Ani Pharmaceuticals Announces Fda Approval and Commercial Availability of New 1-Ml Vial Size of Purified Cortrophin®? Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Arthritis Flares

Ani Pharmaceuticals Announces the Fda Approval and Launch of Estradiol Gel, 0.1%

ANI Pharmaceuticals, Inc. Announces Board Changes

President recently sold €3.0m worth of stock

Second quarter 2023 earnings released: EPS: US$0.30 (vs US$0.94 loss in 2Q 2022)

Forecast breakeven date moved forward to 2023

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2023

ANI Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

New minor risk - Profitability

ANI Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $75.000033 million.

First quarter 2023 earnings released: EPS: US$0.063 (vs US$1.27 loss in 1Q 2022)

ANI Pharmaceuticals, Inc. Raises Revenue Guidance for Full Year 2023

Full year 2022 earnings released: US$3.05 loss per share (vs US$3.40 loss in FY 2021)

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Levocarnitine Tablets USP

ANI Pharmaceuticals Announces the FDA Approval and Launch of Fluoxetine Oral Solution USP

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Trimethoprim Tablets USP

High number of new directors

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$0.37 loss in 3Q 2021)

Ani Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Year 2022

ANI Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 09, 2022

ANI Pharmaceuticals, Inc. Appoints Krista Davis as Chief Human Resources Officer

ANI Pharmaceuticals Announces the Launch of Prochlorperazine Maleate Tablets USP

Key Executive recently sold €661k worth of stock

ANI Pharmaceuticals, Inc. Announces FDA Approval and Imminent Launch of Dexamethasone Tablets USP

ANI Pharmaceuticals, Inc. Reports Impairment Charge for the Second Quarter Ended June 30, 2022

Second quarter 2022 earnings released: US$0.94 loss per share (vs US$1.17 loss in 2Q 2021)

Ani Pharmaceuticals Announces the Launch of Acebutolol Hydrochloride Capsules USP

ANI Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 08, 2022

ANI Pharmaceuticals Appoints Meredith W. Cook as SVP, General Counsel and Corporate Secretary

ANI Pharmaceuticals Announces the FDA Approval and Imminent Launch of Fludrocortisone Acetate Tablets USP

ANI Pharmaceuticals, Inc. Provides Revenue Guidance for the Fiscal Year 2022

First quarter 2022 earnings released: US$1.27 loss per share (vs US$0.007 profit in 1Q 2021)

High number of new directors

ANI Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 10, 2022

ANI Pharmaceuticals, Inc. Announces the Launch of Misoprostol Tablets

Chairman recently bought €126k worth of stock

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

ANI Pharmaceuticals Announces Executive Changes

ANI Pharmaceuticals, Inc., Annual General Meeting, Apr 27, 2022

Oakrum Pharma and ANI Pharmaceuticals Announce the Launch of Betaine Anhydrous Powder, the first Generic Version of Cystadane® Powder, Including 180 Days of Exclusivity

ANI Pharmaceuticals Announces Commercial Availability of Purified Cortrophin™ Gel for Multiple Chronic Autoimmune Disorders